Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Covington
UBS
QuintilesIMS
Dow
McKesson
Argus Health
Harvard Business School
Fuji

Generated: January 19, 2018

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries and twenty-five supplementary protection certificates in ten countries.

Summary for Wyeth Pharms Inc
International Patents:310
US Patents:18
Tradenames:29
Ingredients:19
NDAs:31

Drugs and US Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc ZOSYN IN PLASTIC CONTAINER piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050750-001 Feb 24, 1998 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PHOSPHOLINE IODIDE echothiophate iodide FOR SOLUTION;OPHTHALMIC 011963-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc PIPRACIL piperacillin sodium INJECTABLE;INJECTION 050545-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc PROTONIX pantoprazole sodium FOR SUSPENSION, DELAYED RELEASE;ORAL 022020-001 Nov 14, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc ZOSYN piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050684-001 Oct 22, 1993 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc ORUVAIL ketoprofen CAPSULE, EXTENDED RELEASE;ORAL 019816-003 Feb 8, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-002 Oct 20, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PREMARIN estrogens, conjugated TABLET;ORAL 004782-006 Jul 16, 2003 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc INDERAL propranolol hydrochloride TABLET;ORAL 016418-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc PREMPHASE 14/14 estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020527-002 Nov 17, 1995 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc PREMPHASE (PREMARIN;CYCRIN 14/14) estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020303-002 Dec 30, 1994 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-003 Jan 31, 1991 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc TRIPHASIL-28 ethinyl estradiol; levonorgestrel TABLET;ORAL-28 019190-001 Nov 1, 1984 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-001 Oct 25, 1996 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc TRIPHASIL-28 ethinyl estradiol; levonorgestrel TABLET;ORAL-28 019190-001 Nov 1, 1984 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc PREMPRO estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020527-005 Jun 4, 2003 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc PREMARIN estrogens, conjugated INJECTABLE;INJECTION 010402-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for WYETH PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 5/8/2015
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2/29/2012
➤ Subscribe For Injection 12 g/1.5 g per vial (pharmacy bulk) ➤ Subscribe 12/6/2011
➤ Subscribe Tablets 0.09 mg/0.02 mg ➤ Subscribe 10/5/2007
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 5/3/2007
➤ Subscribe Tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg ➤ Subscribe 11/3/2005
➤ Subscribe Delayed-release Tablets 20 mg and 40 mg ➤ Subscribe 2/2/2004

Non-Orange Book US Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508 Succinate salt of O-desmethyl-venlafaxine ➤ Subscribe
7,291,347 Succinate salt of O-desmethyl-venlafaxine ➤ Subscribe
7,498,312 Compositions containing piperacillin and tazobactam useful for injection ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Wyeth Pharms Inc Drugs

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
156 Luxembourg ➤ Subscribe PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
C0009 Belgium ➤ Subscribe PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0443983/03 Switzerland ➤ Subscribe PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C/GB96/056 United Kingdom ➤ Subscribe PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
C/GB02/037 United Kingdom ➤ Subscribe PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0025 Belgium ➤ Subscribe PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
00221 Netherlands ➤ Subscribe PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
2011 00026 Denmark ➤ Subscribe PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2016 00016 Denmark ➤ Subscribe PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
C/GB99/008 United Kingdom ➤ Subscribe PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
US Army
Johnson and Johnson
QuintilesIMS
Queensland Health
Julphar
Teva
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot